Last reviewed · How we verify
NCT03425448
Neutrolin Versus Heparin for Locking Hemodialysis Catheters
NA trial testing Heparin in Hemodialysis Catheter Infection in 192 participants. Status unknown.
4 October 2020
Quick facts
| Lead sponsor | King Abdullah International Medical Research Center |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 192 |
| Start date | 4 April 2019 |
| Primary completion | 4 October 2020 |
| Estimated completion | 4 April 2021 |
Drugs / interventions tested
Conditions studied
- Hemodialysis Catheter Infection — all drugs for Hemodialysis Catheter Infection →
- Catheter Thrombosis — all drugs for Catheter Thrombosis →
Sponsor
King Abdullah International Medical Research Center — full company profile →
Who can join
18 and older, any sex, with Hemodialysis Catheter Infection or Catheter Thrombosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Hemodialysis catheter related bacterial infections represent a major cause of mortality and morbidity in the hemodialysis population. Several locking agents had been tried with variable degree of success but not without side effects. Neutrolin catheter locking agent comprises of heparin,citrate and trauolidine that had been studied in a prospective study in Germany, and it demonstrated a very good result in terms of reducing the catheter related infections and thrombosis. This study is a multi-center, double-blind RCT comparing the hemodialysis catheter locking solution Neutrolin with heparin in reducing the rate of catheter related bacterial infection and thrombosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03425448
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Heparin
Trials testing the same drug.
- NCT06453876 — PERCUTANEOUS EMBOLECTOMY, ULTRASOUND ASSISTED LOW DOSE THROMBOLYSIS OR HEPARIN FOR INTERMEDIATE HIGH RISK PULMONARY EMBO · Phase 3 · not yet recruiting
- NCT06381661 — Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Tra · Phase 2 · not yet recruiting
- NCT06676085 — A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation · NA · recruiting
- NCT06549842 — Safe and Fast Radial Hemostasis Using Synergistic Strategies: SAFE & FAST Trial · NA · completed
- NCT05848713 — AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia · Phase 3 · recruiting
Other King Abdullah International Medical Research Center trials
Trials by the same sponsor.
- NCT07089251 — The Perioperative Outcome of Epinephrine Infusion and Tranexamic Acid in Knee Arthroplasty Surgery · Phase 4 · recruiting
- NCT06404996 — Smart-phone Application Versus Conventional Paper for the Documentation of Voiding Dysfunction in Children · NA · not yet recruiting
- NCT06595550 — The Effect of Whey Protein Consumption on Hypoglycemia in Adults with Type 1 Diabetes During Fasting Ramadan. · NA · completed
- NCT06627166 — Viral Etiology of Severe Acute Respiratory InFection in CriticallY Ill Patients Registry · terminated
- NCT05421468 — Timing of Thyroxine Dose In Ramadan · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03425448 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by King Abdullah International Medical Research Center
- Last refreshed: 5 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03425448.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing